Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025)

Neurogene (NGNE) reported Asset Writedowns and Impairment of $120000.0 for Q4 2025, up 31.87% quarter-over-quarter from $91000.0 in Q1 2024.

Neurogene (NGNE) Asset Writedowns and Impairment (2023 - 2025) Analysis & Trends

Neurogene has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $120000.0 in Q4 2025.

For the quarter ending Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $120000.0; the trailing twelve-month figure through Dec 2025 stood at $120000.0 (up 31.87% YoY), and the FY2025 full-year result was $120000.0, up 31.87% from the prior year.
Asset Writedowns and Impairment for Q4 2025 stood at $120000.0, up from $91000.0 in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $120000.0 in Q4 2025, with the low at $91000.0 in Q1 2024.
Historically, Asset Writedowns and Impairment has averaged $103666.7 across 3 years, with a median of $100000.0 in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Neurogene	216.17 Mn	216.17 Mn	-

Download Data